151
|
Tang Q, Li X, Yu L, Hao Y, Lu G. Preoperative ropivacaine with or without tramadol for femoral nerve block in total knee arthroplasty. J Orthop Surg (Hong Kong) 2016; 24:183-7. [PMID: 27574260 DOI: 10.1177/1602400213] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
PURPOSE To compare the analgesic effect of preoperative ropivacaine with or without tramadol for femoral nerve block in total knee arthroplasty (TKA). METHODS 14 men and 46 women aged 59 to 80 years who were American Society of Anesthesiologists (ASA) grade I or II and were scheduled for TKA were randomised to receive preoperative femoral nerve block with 20 ml of 0.375% ropivacaine plus tramadol 0 mg (n=15), 50 mg (n=15), or 100 mg (n=15), or no preoperative femoral nerve block (control) [n=15]. Femoral nerve block was performed by a single anaesthesiologist before the standardised combined spinal epidural anaesthesia. Postoperatively, patientcontrolled analgesia was given. The visual analogue score (VAS) for pain at rest and on movement was recorded at 8, 12, 24, 48, and 72 hours. Passive knee range of motion (ROM) was measured at 24, 48, and 72 hours. RESULTS The 4 groups were comparable in terms of age, gender, weight, ASA grade, and operating time. Compared with patients who received no femoral nerve block or ropivacaine alone, those who received femoral nerve block with 20 ml of 0.375% ropivacaine plus tramadol 50 mg or 100 mg recorded a lower VAS for pain at rest and on movement at 8 to 72 hours, longer sensory and motor block time, and lower demand, delivery, and total amount of patientcontrolled analgesia. The passive knee ROM at 24 to 72 hours was greater in patients with femoral nerve block than in those without. CONCLUSION Preoperative femoral nerve block with 20 ml of 0.375% ropivacaine and 100 mg tramadol resulted in the best analgesic effect.
Collapse
|
152
|
Moreau M, Yasmin-Karim S, Hao Y, Ngwa W. SU-F-T-59: The Effect of Radiotherapy Dose On Immunoadjuvants. Med Phys 2016. [DOI: 10.1118/1.4956194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
153
|
Toomeh D, Ngwa W, Sajo E, Hao Y, Gadoue S. WE-FG-BRA-09: Using Graphene Oxide Nano Flakes During Image Guided Radiotherapy to Minimize the Potential of Cancer Recurrence Or Metastasis. Med Phys 2016. [DOI: 10.1118/1.4957909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
154
|
Mueller R, Hao Y, Hesser J, Ngwa W. TU-H-CAMPUS-TeP3-02: In-Situ Dose Painting Using Gold Nanoparticles Released From Cylindrically Shaped Fiducials During External Beam Radiation Therapy. Med Phys 2016. [DOI: 10.1118/1.4957705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
155
|
Chen J, Li T, Hao Y, Chong H, Yeo S. THU0474 The Influence of Osteoporotic Hip Fracture after Total Knee Arthroplasty: A Propensity-Matched Cohort Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
156
|
Lin Y, Xu Z, Yu D, Lu L, Yin M, Tavakoli MM, Chen X, Hao Y, Fan Z, Cui Y, Li D. Dual-Layer Nanostructured Flexible Thin-Film Amorphous Silicon Solar Cells with Enhanced Light Harvesting and Photoelectric Conversion Efficiency. ACS APPLIED MATERIALS & INTERFACES 2016; 8:10929-10936. [PMID: 27052357 DOI: 10.1021/acsami.6b02194] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Three-dimensional (3-D) structures have triggered tremendous interest for thin-film solar cells since they can dramatically reduce the material usage and incident light reflection. However, the high aspect ratio feature of some 3-D structures leads to deterioration of internal electric field and carrier collection capability, which reduces device power conversion efficiency (PCE). Here, we report high performance flexible thin-film amorphous silicon solar cells with a unique and effective light trapping scheme. In this device structure, a polymer nanopillar membrane is attached on top of a device, which benefits broadband and omnidirectional performances, and a 3-D nanostructure with shallow dent arrays underneath serves as a back reflector on flexible titanium (Ti) foil resulting in an increased optical path length by exciting hybrid optical modes. The efficient light management results in 42.7% and 41.7% remarkable improvements of short-circuit current density and overall efficiency, respectively. Meanwhile, an excellent flexibility has been achieved as PCE remains 97.6% of the initial efficiency even after 10 000 bending cycles. This unique device structure can also be duplicated for other flexible photovoltaic devices based on different active materials such as CdTe, Cu(In,Ga)Se2 (CIGS), organohalide lead perovskites, and so forth.
Collapse
|
157
|
Sun Q, Zhao H, Zhou M, Gao L, Hao Y. Performance Enhancement of Small Molecular Solar Cells by Bilayer Cathode Buffer. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY 2016; 16:3831-3834. [PMID: 27451719 DOI: 10.1166/jnn.2016.11888] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
An effective composite bilayer cathode buffer structure is proposed for use in small molecular solar cells. CsF was doped in Alq3 to form the first cathode buffer, leading to small serial resistances. BCP was used as the second cathode buffer to block the holes to the electrode. The optimized bilayer cathode buffer significantly increased the short circuit and fill factor of devices. By integrating this bilayer cathode buffer, the CuPc/C60 small molecular heterojunction cell exhibited a power conversion efficiency of up to 0.8%, which was an improvement of 56% compared to a device with only the Alq3 cathode buffer. Meanwhile, the bilayer cathode buffer still has a good protective effect on the performance of the device.
Collapse
|
158
|
Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guérin A. Abstract P4-13-14: Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Treatment guidelines for hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) recommend extending the time on treatment (TOT) of endocrine therapy (ET) prior to the initiation of chemotherapy (CT) to avoid its serious side effects and preserve patients' quality of life. Everolimus-based therapy (EVE), fulvestrant monotherapy (FUL mono), and capecitabine monotherapy (CAP mono) are among the latest ET and CT agents approved for the treatment of HR+/HER2- mBC in the US. This retrospective claims analysis compared TOT among HR+/HER2- mBC patients who received EVE versus those who received FUL mono or CAP mono respectively.
Methods:
Postmenopausal women with HR+/HER2- mBC who initiated ≥ 1 new line of therapy for mBC between 7/20/2012 (the approval date of EVE, the latest of all three therapies) and 3/31/2014 (which allowed for ≥ 3 months of potential follow-up) after a non-steroidal aromatase inhibitor were identified from the MarketScan and PharMetrics databases (2002Q1-2014Q2) using an algorithm adapted from the literature. Treatment discontinuation was defined as a treatment gap of ≥ 60 days. Patients' lines of therapies were classified into mutually-exclusive regimen groups (i.e., EVE, FUL mono, and CAP mono) and followed until discontinuation of the line of therapy, end of insurance eligibility, or data cut-off (06/30/2014). Patients who did not discontinue their treatment were censored at the end of follow-up. TOT was compared between EVE versus FUL mono and versus CAP mono using Kaplan-Meier (K-M) analyses with log-rank tests and multivariable Cox models adjusting for the line of therapy and differences in patient characteristics, including age, insurance type, de novo vs non-de-novo mBC, prior use of CT for mBC, sites of metastases (e.g., bone, brain, and visceral), and Charlson comorbidity index.
Results:
Across the first four lines of therapies for mBC, a total of 940 EVE, 953 FUL mono, and 721 CAP mono regimens were included. Based on the different lines of therapies, the K-M estimators of median TOT ranged from 5.5 to 7.2 months for EVE, 4.9 to 8.4 months for FUL mono, and 3.5 to 6.0 months for CAP mono.
Table 1. Comparison of TOT between EVE, FUL mono, and CAP mono by line of therapy Median TOT (months) EVEFUL monoCAP monoLine 16.28.43.5*Line 26.25.64.6*Line 37.25.3*6.0*Line 45.54.95.1**indicates p-value <0.05 for pairwise log-rank tests in comparison with EVE.
Pooling all lines of therapies, EVE was associated with significantly longer TOT compared to FUL mono (multivariable-adjusted hazard ratio [HR] = 0.87, 95% confidence interval [CI]: 0.76-0.99) or CAP mono (multivariable-adjusted HR = 0.73, 95% CI: 0.64-0.83). Similar results were observed in each line of therapy.
Conclusions:
This real-world US claims study of postmenopausal women with HR+/HER2- mBC showed that patients receiving EVE experienced significantly longer TOT than those receiving FUL mono or CAP mono, suggesting a comparative advantage of EVE in extending the duration of ET.
Citation Format: Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guérin A. Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-14.
Collapse
|
159
|
Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ. Abstract P2-08-20: Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) is the most common type of metastatic breast cancer (mBC). While overall the prognosis among these patients is poor with short progression-free survival (PFS) and overall survival (OS), those with multiple metastatic sites (multiple mets) may have even worse clinical outcomes due to multiple organ involvement. This real-world study examined clinical outcomes among HR+/HER2- mBC patients with multiple mets.
Methods:
In this retrospective chart review, a sample of postmenopausal women with HR+/HER2- mBC was collected from community-based oncology practices in the US. Patients were required to have failed a non-steroidal aromatase inhibitor and later initiated a new treatment (defined as the index therapy) for mBC between July 1, 2012 and April 15, 2013. Patients were classified into two mutually exclusive groups: multiple mets or single metastatic site (single met), based on the number of non-lymph-node metastatic sites at index therapy initiation. PFS, time on treatment (TOT), and OS were compared between the two study groups using Kaplan-Meier analyses with log-rank tests and multivariable Cox proportional hazards models adjusting for baseline characteristics, including age, race, insurance, mBC type, and months from initiation of last adjuvant endocrine therapy to mBC diagnosis, index therapy type, index therapy line, adjusted Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) performance status, and prior chemotherapy for mBC. Patients without an event were censored at the last follow-up. In addition, separate Cox proportional hazard models were conducted including an interaction term between line of therapy and study group to assess the impact of multiple mets on clinical outcomes across different lines of therapy.
Results:
A total of 408 patients in the single met group and 291 patients in the multiple mets group were included. Patients with multiple mets had worse ECOG performance status and a higher rate of prior chemotherapy use for mBC compared with patients in the single met group. Relative to patients with single met, patients with multiple mets were associated with significantly shorter PFS (log-rank test p<0.001, hazard ratio (HR)=1.68, 95% confidence interval (CI): 1.32-2.14), TOT (log-rank test p<0.001, HR=1.37, 95% CI: 1.09-1.72) and OS (log-rank test p<0.001, HR=1.71, 95% CI: 1.12-2.63). Similar outcomes were observed in each line of therapy.
Table 1. Multivariable -adjusted comparisons of PFS, TOT, and OS between patients with multiple mets and single met by line of therapy PFSTOTOSMultiple mets vs. single metHR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-valueLine of therapy 11.51 (1.04,2.19)0.030*1.22 (0.86,1.73)0.2561.94 (1.06,3.56)0.032*Line of therapy 21.79 (1.17,2.74)0.008*1.50 (1.02,2.21)0.042*2.35 (1.03,5.38)0.043*Line of therapy 3+1.82 (1.18,2.83)0.007*1.46 (0.97,2.21)0.0721.03 (0.48,2.20)0.936*P < 0.05
Conclusion:
Among HR+/HER2- mBC patients, those with multiple mets had significantly worse clinical outcomes, highlighting substantial disease burden and unmet need for more efficacious treatment for these patients.
Citation Format: Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-20.
Collapse
|
160
|
Li N, Hao Y, Lin PL, Koo V, Ohashi E, Wu EQ, Xie J. Abstract P4-13-13: Real-world effectiveness of everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with liver metastasis or multiple metastatic sites. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Liver metastasis and multiple metastatic sites are associated with higher risk of progression or death among women with hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC). Traditional treatments, like endocrine monotherapy (ET mono) or chemotherapy (CT), have limited effectiveness in these high-risk patients. Everolimus-based therapy (EVE) is a new treatment option with different mechanism of action. This study examined the real-world comparative effectiveness of EVE vs. ET mono or CT in patients with liver metastasis or multiple metastatic sites.
Methods:
A sample of postmenopausal women with HR+/HER2- mBC was obtained through a retrospective chart review of community-based oncology practices in the US. All patients initiated EVE, ET mono, or CT (defined as the index therapy) for mBC between July 2012 and April 2013 after the failure of a non-steroidal aromatase inhibitor. Patients with liver metastasis and those with multiple metastatic sites (i.e., ≥2 non-lymph-node metastases) at the index therapy initiation were analyzed separately. In each group, progression-free survival (PFS) and time on treatment (TOT) were compared between EVE vs. ET mono or CT, respectively, using Kaplan-Meier analyses with log-rank tests and Cox proportional hazards models adjusting for patient and disease characteristics, such as age, mBC type, performance status, tumor burden, and prior treatment. Patients without an event were censored at the last follow-up.
Results:
A total of 202 patients had liver metastasis, including 82 treated with EVE, 49 with ET mono, and 71 with CT. EVE patients had more severe mBC than ET mono patients and less severe mBC than CT patients, as indicated by proportion of patients receiving prior CT for mBC and tumor burden. Compared with ET mono, EVE was associated with significantly longer PFS (log-rank test p=0.049; hazard ratio (HR)=0.48, 95% confidence interval (CI): 0.27-0.87) and TOT (log-rank test p=0.054, HR=0.49, 95% CI: 0.28-0.86). Similarly, compared with CT, EVE was associated with significantly longer PFS (log-rank test p=0.024, HR=0.76, 95% CI: 0.44-1.32) and TOT (log-rank test p<0.001, HR=0.35, 95% CI: 0.22-0.55).
A total of 265 patients had multiple metastatic sites, including 100 treated with EVE, 79 with ET mono, and 86 with CT. Similarly, EVE patients had more severe mBC than ET mono patients and less severe mBC than CT patients, as indicated by tumor burden. Compared with ET mono, EVE was associated with significantly longer PFS (log-rank test p=0.043, HR=0.62, 95% CI: 0.41-0.95) and TOT (log-rank test p=0.054, HR=0.64, 95% CI: 0.42-0.97). Compared with CT, EVE was also associated with longer PFS (log-rank test p=0.004, HR=0.60, 95% CI: 0.39-0.92) and TOT (log-rank test p<0.001, HR=0.36, 95% CI: 0.24-0.53).
Conclusion:
In this retrospective chart review of HR+/HER2- mBC patients, EVE was associated with significantly longer PFS and TOT compared with ET mono or CT in high-risk patients with liver metastasis or multiple metastatic sites.
Citation Format: Li N, Hao Y, Lin PL, Koo V, Ohashi E, Wu EQ, Xie J. Real-world effectiveness of everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with liver metastasis or multiple metastatic sites. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-13.
Collapse
|
161
|
Hao Y, Liu JR, Zhang Y, Yang PG, Feng YJ, Cui YJ, Yang CH, Gu XH. The microRNA expression profile in porcine skeletal muscle is changed by constant heat stress. Anim Genet 2016; 47:365-9. [DOI: 10.1111/age.12419] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2015] [Indexed: 01/22/2023]
|
162
|
Zhang F, Song J, Chen M, Liu J, Hao Y, Wang Y, Qu J, Zeng P. Enhanced perovskite morphology and crystallinity for high performance perovskite solar cells using a porous hole transport layer from polystyrene nanospheres. Phys Chem Chem Phys 2016; 18:32903-32909. [DOI: 10.1039/c6cp06405a] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
(1) Porous-PEDOT:PSS from PS nanospheres. (2) The perovskite quality is improved, with the improved crystallinity and enhanced grain sizes. (3) High-performance perovskite solar cells.
Collapse
|
163
|
Zhang B, Hao Y, Jia F, Li X, Tang Y, Zheng H, Liu W. Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep related breathing disorders. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.1344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
164
|
Hao Y, Wang X, Wang L, Lu Y, Mao Z, Ge S, Dai K. Zoledronic acid suppresses callus remodeling but enhances callus strength in an osteoporotic rat model of fracture healing. Bone 2015; 81:702-711. [PMID: 26434668 DOI: 10.1016/j.bone.2015.09.018] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 09/29/2015] [Accepted: 09/30/2015] [Indexed: 11/18/2022]
Abstract
MINI-ABSTRACT In this study, we demonstrated that the use of zoledronic acid does not impair fracture healing, but results in superior callus size and resistance at the fracture site, which could be the consequence of a lower rate of bone turnover due to its anti-catabolic effect. OBJECTIVE To investigate the effect of inhibition of bone remodeling by the bisphosphonate, zoledronic acid, on callus properties in an osteoporotic rat model of fracture healing. METHODS Ovariectomized (OVX) rats were randomly divided into four treatment groups (n=24 per group): saline control (CNT); and three systemic zoledronic acid-injected groups (0.1mg/kg), administered 1 day (ZOLD1), 1 week (ZOLW1), and 2 weeks (ZOLW2) after fracture. Rats were killed at either 6 or 12 weeks postoperatively. Postmortem analyses included radiography, microcomputed tomography, histology, histomorphometry, biomechanical tests, and nanoindentation tests. RESULTS Treatment with zoledronic acid led to a significant increase in trabecular bone volume within the callus, as well as in callus resistance, compared to those in the saline control rats; delayed administration (ZOLW2) reduced intrinsic material properties, including ultimate stress and elastic modulus, and microarchitecture parameters, including bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), and connectivity density (Conn.D), compared with ZOLD1 at 12 weeks after surgery. OVX had a negative effect on the progression of endochondral ossification at 6 weeks. Zoledronic acid administration at an early stage following fracture may bind to early callus, and thus not affect subsequent callus formation and endochondral ossification, while delayed administration (ZOLW2) mildly suppresses bony callus remodeling. CONCLUSION The superior results obtained with zoledronic acid (ZOLD1, ZOLW1, and ZOLW2) compared to CNT in terms of callus size and resistance could be the consequence of a lower rate of bone turnover at the fracture site due to the anti-catabolic effect of zoledronic acid. Mild suppression of callus remodeling by delayed administration did not impair the initial phase of the fracture healing process.
Collapse
|
165
|
Yang F, Zhang Y, Hao Y, Cui Y, Wang W, Ji T, Shi F, Wei B. Visibly transparent organic photovoltaic with improved transparency and absorption based on tandem photonic crystal for greenhouse application. APPLIED OPTICS 2015; 54:10232-10239. [PMID: 26836682 DOI: 10.1364/ao.54.010232] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We demonstrate a visible transparent organic photovoltaic (OPV) with improved transmission and absorption based on tandem photonic crystals (TPCs) for greenhouse applications. The proposed device has an average transmittance of 40.3% in the visible range of 400-700 nm and a high quality transparency spectrum for plant growth with a crop growth factor of 41.9%, considering the weight of the AM 1.5G solar spectrum. Compared with the corresponding transparent OPV without photonic crystals, an enhancement of 20.7% in the average transmittance and of 24.5% in the crop growth factor are achieved. Detailed investigations reveal that the improved transmittance is attributed to the excitation of the optical Tamm state and the light interference effect in TPC. Concomitantly, the total absorption efficiency in the active layer of the designed TPC based transparent OPV reaches 51.5%, being 1.78% higher than that of the transparent OPV without PC and 76% of that of the opaque counterpart. The improved absorption originates from the Bragg forbidden reflectance of TPC. Overall, our proposal achieves the optimized utilization of sunlight by light manipulation of TPC.
Collapse
|
166
|
Hao Y, Altundal Y, Moreau M, Sajo E, Ngwa W. New Potential for Employing Fiducials to Combat Metastasis via the Abscopal Effect. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.2148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
167
|
Zhang W, Gu Y, Hao Y, Sun Q, Konior K, Wang H, Zilberberg J, Lee WY. Well plate-based perfusion culture device for tissue and tumor microenvironment replication. LAB ON A CHIP 2015; 15:2854-2863. [PMID: 26021852 PMCID: PMC4470735 DOI: 10.1039/c5lc00341e] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
There are significant challenges in developing in vitro human tissue and tumor models that can be used to support new drug development and evaluate personalized therapeutics. The challenges include: (1) working with primary cells which are often difficult to maintain ex vivo, (2) mimicking native microenvironments from which primary cells are harvested, and (3) the lack of culture devices that can support these microenvironments to evaluate drug responses in a high-throughput manner. Here we report a versatile well plate-based perfusion culture device that was designed, fabricated and used to: (1) ascertain the role of perfusion in facilitating the expansion of human multiple myeloma cells and evaluate drug response of the cells, (2) preserve the physiological phenotype of primary murine osteocytes by reconstructing the 3D cellular network of osteocytes, and (3) circulate primary murine T cells through a layer of primary murine intestine epithelial cells to recapitulate the interaction of the immune cells with the epithelial cells. Through these diverse case studies, we demonstrate the device's design features to support: (1) the convenient and spatiotemporal placement of cells and biomaterials into the culture wells of the device; (2) the replication of tissues and tumor microenvironments using perfusion, stromal cells, and/or biomaterials; (3) the circulation of non-adherent cells through the culture chambers; and (4) conventional tissue and cell characterization by plate reading, histology, and flow cytometry. Future challenges are identified and discussed from the perspective of manufacturing the device and making its operation for routine and wide use.
Collapse
|
168
|
Hao Y, Cifter G, Altundal Y, Sinha N, Moreau M, Sajo E, Makrigiorgos G, Ngwa W. MO-FG-BRA-04: Leveraging the Abscopal Effect Via New Design Radiotherapy Biomaterials Loaded with Immune Checkpoint Inhibitors. Med Phys 2015. [DOI: 10.1118/1.4925408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
169
|
Wang M, Jiang X, Wu W, Hao Y, Su Y, Cai L, Xiang M, Liu X. Psychrophilic fungi from the world's roof. PERSOONIA 2015; 34:100-12. [PMID: 26240448 PMCID: PMC4510274 DOI: 10.3767/003158515x685878] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Accepted: 03/05/2014] [Indexed: 12/05/2022]
Abstract
During a survey of cold-adapted fungi in alpine glaciers on the Qinghai-Tibet Plateau, 1 428 fungal isolates were obtained of which 150 species were preliminary identified. Phoma sclerotioides and Pseudogymnoascus pannorum were the most dominant species. Psychrotolerant species in Helotiales (Leotiomycetes, Ascomycota) were studied in more detail as they represented the most commonly encountered group during this investigation. Two phylogenetic trees were constructed based on the partial large subunit nrDNA (LSU) to infer the taxonomic placements of these strains. Our strains nested in two well-supported major clades, which represented Tetracladium and a previously unknown lineage. The unknown lineage is distant to any other currently known genera in Helotiales. Psychrophila gen. nov. was therefore established to accommodate these strains which are characterised by globose or subglobose conidia formed from phialides on short or reduced conidiophores. Our analysis also showed that an LSU-based phylogeny is insufficient in differentiating strains at species level. Additional analyses using combined sequences of ITS+TEF1+TUB regions were employed to further investigate the phylogenetic relationships of these strains. Together with the recognisable morphological distinctions, six new species (i.e. P. antarctica, P. lutea, P. olivacea, T. ellipsoideum, T. globosum and T. psychrophilum) were described. Our preliminary investigation indicates a high diversity of cold-adapted species in nature, and many of them may represent unknown species.
Collapse
|
170
|
Li K, Hao Y, Hu X, Xie D, Li X, Zheng H, Fu Y, Chen Y, Zheng Y. The effect of sensorimotor training performed by carers on home-based rehabilitation in stroke patients. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1693] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
171
|
Liu W, Xiao J, Ji F, Xie Y, Hao Y. Intrinsic and extrinsic risk factors for nonunion after nonoperative treatment of midshaft clavicle fractures. Orthop Traumatol Surg Res 2015; 101:197-200. [PMID: 25703151 DOI: 10.1016/j.otsr.2014.11.018] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 08/21/2014] [Accepted: 11/14/2014] [Indexed: 02/02/2023]
Abstract
BACKGROUND The optimal treatment of midshaft clavicle fractures remains controversial. Nonunion is usually considered to be an uncommon complication following a nonoperatively treated clavicle fracture. HYPOTHESIS Not every midshaft clavicular fractures shares the same risk of developing nonunion after nonoperative treatment. The present study was performed to identify the intrinsic and extrinsic independent factors that are independently predictive of nonunion in patients with midshaft clavicular fractures after nonoperative treatment. MATERIALS AND METHODS We performed a retrospective study of a series of 804 patients (391 men and 413 women with a median age of 51.3 years) with a radiographically confirmed midshaft clavicle fracture, which was treated nonoperatively. There were 96 patients who underwent nonunion. Putative intrinsic (patient-related) and extrinsic (injured-related) risk factors associated with nonunion were determined with the use of bivariate and multivariate statistical analyses. RESULTS By bivariate analysis, the risk of nonunion was significantly increased by several intrinsic risk factors including age, sex, and smoking and extrinsic risk factors including displacement of the fracture and the presence of comminution (P<0.05 for all). On multivariate analysis, smoking (OR=4.16, 95% CI: 1.01-14.16), fracture displacement (OR=7.81, 95% CI: 2.27-25.38) and comminution of fracture (OR=3.86, 95% CI: 1.16-13.46) were identified as independent predictive factors. CONCLUSION The risk factors for nonunion after nonoperative treatment of midshaft clavicle fractures are multifactorial. Smoking, fracture displacement and comminution of fracture are independent predictors for an individual likelihood of nonunion. Further studies are still required to evaluate these factors in the future. LEVEL OF EVIDENCE Level III, case-control study.
Collapse
|
172
|
Lu XL, Zhang JW, Zhang CF, Zhang JC, Hao Y. Highly ordered core–shell CoFe2O4–BiFeO3 nanocomposite arrays from dimension confined phase separation and their interfacial magnetoelectric coupling properties. RSC Adv 2015. [DOI: 10.1039/c5ra05106a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
With dimension confinement, highly ordered core–shell CoFe2O4–BiFeO3 nanocomposite arrays were obtained from the self-assembly phase separation.
Collapse
|
173
|
Yuan S, Hao Y, Miao Y, Sun Q, Li Z, Cui Y, Wang H, Shi F, Xu B. Reduced efficiency roll-off in phosphorescent OLEDs with a stack emitting layer facilitating triplet exciton diffusion. RSC Adv 2015. [DOI: 10.1039/c5ra18769a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A high efficiency and low efficiency roll-off phosphorescent organic light-emitting diode (PHOLED) is demonstrated based on a stack emitting layer by alternating [CBP : 4 wt% Ir(ppy)3 (5 nm)] and [CBP : 8 wt% Ir(ppy)3 (5 nm)] ultrathin films.
Collapse
|
174
|
Miao Y, Du X, Wang H, Liu H, Jia H, Xu B, Hao Y, Liu X, Li W, Huang W. Simplified phosphorescent organic light-emitting devices using heavy doping with an Ir complex as an emitter. RSC Adv 2015. [DOI: 10.1039/c4ra13308k] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Simplified PhOLEDs based on heavy doping with the light-emitting layer (EML) of CBP: 25 wt% Ir(ppy)3 (30 nm) shows a peak current efficiency of 46.8 cd A−1, which is 1.64 times that of the reference device with the EML of CBP: 8 wt% Ir(ppy)3 (30 nm).
Collapse
|
175
|
Hao Y, Gu X. Effects of heat shock protein 90 expression on pectoralis major oxidation in broilers exposed to acute heat stress. Poult Sci 2014; 93:2709-17. [DOI: 10.3382/ps.2014-03993] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
176
|
Wang Z, Li Z, Zhang H, Liu W, Xu X, Si C, Cui Y, Sun Q, Wang H, Shi F, Hao Y. A Conjugated Random Copolymer of Benzodithiophene-Difluorobenzene-Diketopyrrolopyrrole with Full Visible-Light Absorption for Bulk-Heterojunction Solar Cells. MACROMOL CHEM PHYS 2014. [DOI: 10.1002/macp.201400334] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
177
|
Roboz G, Ravandi F, Kropf P, Yee K, O'Connell C, Griffiths E, Stock W, Garcia-Manero G, Jabbour E, Daver N, Pemmaraju N, Issa J, Walsh K, Rizzieri D, Lunin S, Naim S, Hao Y, Azab M, Kantarjian H. Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
178
|
Ferraldeschi R, Slovin S, Hussain S, Saad F, Garcia J, Kabbinavar F, Uppal N, Vogelzang N, Poiesz B, Gelmann E, Picus J, Mahadevan D, Sundar S, Nikapota A, Pacey S, Oganesian A, Manlapaz-Espiritu L, Hao Y, Keer H, de Bono J. A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
179
|
McManus TM, Valiente-Kroon JA, Horsley SAR, Hao Y. Illusions and cloaks for surface waves. Sci Rep 2014; 4:5977. [PMID: 25145953 PMCID: PMC4141251 DOI: 10.1038/srep05977] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Accepted: 07/11/2014] [Indexed: 11/30/2022] Open
Abstract
Ever since the inception of Transformation Optics (TO), new and exciting ideas have been proposed in the field of electromagnetics and the theory has been modified to work in such fields as acoustics and thermodynamics. The most well-known application of this theory is to cloaking, but another equally intriguing application of TO is the idea of an illusion device. Here, we propose a general method to transform electromagnetic waves between two arbitrary surfaces. This allows a flat surface to reproduce the scattering behaviour of a curved surface and vice versa, thereby giving rise to perfect optical illusion and cloaking devices, respectively. The performance of the proposed devices is simulated using thin effective media with engineered material properties. The scattering of the curved surface is shown to be reproduced by its flat analogue (for illusions) and vice versa for cloaks.
Collapse
|
180
|
Mitchell-Thomas RC, Quevedo-Teruel O, McManus TM, Horsley SAR, Hao Y. Lenses on curved surfaces. OPTICS LETTERS 2014; 39:3551-3554. [PMID: 24978534 DOI: 10.1364/ol.39.003551] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
This Letter presents a theory that allows graded index lenses to be mapped onto arbitrary rotationally symmetric curved surfaces. Examples of the Luneburg and Maxwell fish-eye lens are given, for numerous surfaces, always resulting in isotropic permittivity requirements. The performance of these lenses is initially illustrated with full-wave simulations utilizing a waveguide structure. A transformation of the refractive index profiles is then performed to design surface-wave lenses, where the dielectric layer is not only isotropic but also homogenous, demonstrating the applicability and ease of fabrication.
Collapse
|
181
|
Hao Y, Altundal Y, Sajo E, Detappe A, Makrigiorgos G, Berbeco R, Ngwa W. WE-G-BRE-06: New Potential for Enhancing External Beam Radiotherapy for Lung Cancer Using FDA-Approved Concentrations of Cisplatin Or Carboplatin Nanoparticles Administered Via Inhalation. Med Phys 2014. [DOI: 10.1118/1.4889481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
182
|
Wu D, Chen J, Hao Y, Liao C, Huang Y, Mo Y, Wei Y. SU-E-T-36: An Investigation of the Margin From CTV to PTV Using Retraction Method for Cervical Carcinoma. Med Phys 2014. [DOI: 10.1118/1.4888366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
183
|
Wang H, Yang J, Sun J, Xu Y, Wu Y, Dong Q, Wong WY, Hao Y, Zhang X, Li H. Optical and Electroluminescent Studies of White-Light-Emitting Copolymers Based on Poly(9,9-dioctylfluorene) and Fluorenone Derivatives. MACROMOL CHEM PHYS 2014. [DOI: 10.1002/macp.201400070] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
184
|
Thein T, Chan SP, Ng D, Wong J, Hao Y, Leo Y, Lye D. Prolonged fever in adult dengue patients. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.1104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
185
|
Zhang Z, Dai D, Yu K, Yuan F, Jin J, Ding L, Hao Y, Liang F, Liu N, Zhao X, Long J, Xi Y, Sun YY. Association of HLA-B27 and ERAP1 with ankylosing spondylitis susceptibility in Beijing Han Chinese. ACTA ACUST UNITED AC 2014; 83:324-9. [PMID: 24666027 DOI: 10.1111/tan.12334] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Revised: 02/11/2014] [Accepted: 02/13/2014] [Indexed: 12/30/2022]
|
186
|
Wang W, Hao Y, Cui Y, Tian X, Zhang Y, Wang H, Shi F, Wei B, Huang W. High-efficiency, broad-band and wide-angle optical absorption in ultra-thin organic photovoltaic devices. OPTICS EXPRESS 2014; 22:A376-A385. [PMID: 24800293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Metal nanogratings as one of the promising architectures for effective light trapping in organic photovoltaics (OPVs) have been actively studied over the past decade. Here we designed a novel metal nanowall grating with ultra-small period and ultra-high aspect-ratio as the back electrode of the OPV device. Such grating results in the strong hot spot effect in-between the neighboring nanowalls and the localized surface plasmon effect at the corners of nanowalls. These combined effects make the integrated absorption efficiency of light over the wavelength range from 400 to 650 nm in the active layer for the proposed structure, with respect to the equivalent planar structure, increases by 102% at TM polarization and by 36.5% at the TM/TE hybrid polarization, respectively. Moreover, it is noted that the hot spot effect in the proposed structure is more effective for ultra-thin active layers, which is very favorable for the exciton dissociation and charge collection. Therefore such a nanowall grating is expected to improve the overall performance of OPV devices.
Collapse
|
187
|
Wang W, Hao Y, Cui Y, Tian X, Zhang Y, Wang H, Shi F, Wei B, Huang W. High-efficiency, broad-band and wide-angle optical absorption in ultra-thin organic photovoltaic devices. OPTICS EXPRESS 2014; 22 Suppl 2:A376-A385. [PMID: 24922247 DOI: 10.1364/oe.22.00a376] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Metal nanogratings as one of the promising architectures for effective light trapping in organic photovoltaics (OPVs) have been actively studied over the past decade. Here we designed a novel metal nanowall grating with ultra-small period and ultra-high aspect-ratio as the back electrode of the OPV device. Such grating results in the strong hot spot effect in-between the neighboring nanowalls and the localized surface plasmon effect at the corners of nanowalls. These combined effects make the integrated absorption efficiency of light over the wavelength range from 400 to 650 nm in the active layer for the proposed structure, with respect to the equivalent planar structure, increases by 102% at TM polarization and by 36.5% at the TM/TE hybrid polarization, respectively. Moreover, it is noted that the hot spot effect in the proposed structure is more effective for ultra-thin active layers, which is very favorable for the exciton dissociation and charge collection. Therefore such a nanowall grating is expected to improve the overall performance of OPV devices.
Collapse
|
188
|
Jiang H, Sun YM, Hao Y, Yan YP, Chen K, Xin SH, Tang YP, Li XH, Jun T, Chen YY, Liu ZJ, Wang CR, Li H, Pei Z, Shang HF, Zhang BR, Gu WH, Wu ZY, Tang BS, Burgunder JM. Huntingtin gene CAG repeat numbers in Chinese patients with Huntington's disease and controls. Eur J Neurol 2014; 21:637-42. [PMID: 24471773 DOI: 10.1111/ene.12366] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2013] [Accepted: 12/17/2013] [Indexed: 02/05/2023]
|
189
|
Wang W, Cui Y, He Y, Hao Y, Lin Y, Tian X, Ji T, He S. Efficient multiband absorber based on one-dimensional periodic metal-dielectric photonic crystal with a reflective substrate. OPTICS LETTERS 2014; 39:331-334. [PMID: 24562139 DOI: 10.1364/ol.39.000331] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We propose an efficient multiband absorber comprised of a truncated, one-dimensional periodic metal-dielectric photonic crystal and a reflective substrate. The reflective substrate is essentially an optically thick metallic film. Such a planar device is easier to fabricate compared to absorbers with complicated shapes. For a four-unit cell device, all four of the absorption peaks can be optimized with efficiencies higher than 95 percent. Moreover, those absorption peaks are insensitive to the polarization and incident angle. The influences of the geometrical parameters and the refractive index of the dielectric on the device performance also are discussed. Furthermore, we found that the number of absorption peaks within each photonic band precisely corresponds to the number of unit cells because the truncated photonic crystal lattices select resonant modes. We also show that the total absorption efficiency gradually increases when there are more periods of the metal-dielectric composite layer placed on top of the metallic substrate. We expect this work to have potential applications in solar energy harvesting and thermal emission tailoring.
Collapse
|
190
|
Shi YG, Wang D, Zhang JC, Zhang P, Shi XF, Hao Y. Fabrication of single-crystal few-layer graphene domains on copper by modified low-pressure chemical vapor deposition. CrystEngComm 2014. [DOI: 10.1039/c4ce00744a] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Few-layer graphene domains are fabricated by modified LPCVD on Cu and the growth mechanism is schematically shown in the figure.
Collapse
|
191
|
Hao Y, Zhao W, Wang Y, Yu J, Zou D. Assessments of jaw bone density at implant sites using 3D cone-beam computed tomography. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2014; 18:1398-1403. [PMID: 24867520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE To assess the bone density of dental implant sites using CBCT and Simplant software, and establish a quantitative ranges for each bone quality classification according to the classification of bone quality proposed by Lekholm and Zarb. PATIENTS AND METHODS 128 patients' jaw bone were scanned by CBCT, the images were reconstructed by the Simplant software. The bone density of 236 potential implant sites was measured and the results were recorded using Hounsfield units (HU).The data was analyzed with SPSS 19.0 software package for Mann-Whitney U test. RESULTS The anterior mandible mean bone density was (679.6 ± 141.67) HU > anterior maxilla, (460.25 ± 136.42) HU and posterior mandible, (394.4 ± 128.37) HU > posterior maxilla, (229.62 ± 144.48) HU. Quantitative parameters ranged of the bone density according to CBCT as follows: Lekholm and Zarb classification Type D4 was less than 200 HU, Type D2 and Type D3 were more than 200HU and less than 600 HU, and Type D1 was more than 600 HU. CONCLUSIONS Anterior mandible has the highest mean bone density and posterior maxilla has the lowest mean bone density.It is, therefore, proposed that an objective classification which confirms the importance of a site-specific bone tissue evaluation prior to implant installation.
Collapse
|
192
|
Sheng J, Qu X, Zhang X, Zhai Z, Li H, Liu X, Li H, Liu G, Zhu Z, Hao Y, Qin A, Dai K. Coffee, tea, and the risk of hip fracture: a meta-analysis. Osteoporos Int 2014; 25:141-50. [PMID: 24196722 DOI: 10.1007/s00198-013-2563-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 10/16/2013] [Indexed: 10/26/2022]
Abstract
UNLABELLED The present meta-analysis shows no clear association between coffee consumption and the risk of hip fractures. There was a nonlinear association between tea consumption and the risk of hip fracture. Compared to no tea consumption, drinking 1-4 cups of tea daily was associated with a lower risk of hip fracture. INTRODUCTION Prospective cohort and case-control studies have suggested that coffee and tea consumption may be associated with the risk of hip fracture; the results have, however, been inconsistent. We conducted a meta-analysis to assess the association between coffee and tea consumption and the risk of hip fracture. METHODS We performed systematic searches using MEDLINE, EMBASE, and OVID until February 20, 2013, without limits of language or publication year. Relative risks (RRs) with 95% confidence intervals (CI) were derived using random-effects models throughout all analyses. We conducted categorical, dose-response, heterogeneity, publication bias, and subgroup analyses. RESULTS Our study was based on 195,992 individuals with 9,958 cases of hip fractures from 14 studies, including six cohort and eight case-control studies. The pooled RRs of hip fractures for the highest vs. the lowest categories of coffee and tea consumption were 0.94 (95% CI 0.71-1.17) and 0.84 (95% CI 0.66-1.02), respectively. For the dose-response analysis, we found evidence of a nonlinear association between tea consumption and the risk of hip fracture (p(nonlinearity) < 0.01). Compared to no tea consumption, 1-4 cups of tea per day may reduce the risk of hip fracture by 28% (0.72; 95% CI 0.56-0.88 for 1-2 cups/day), 37% (0.63; 95% CI 0.32-0.94 for 2-3 cups/day), and 21% (0.79; 95% CI 0.62-0.96 for 3-4 cups/day). CONCLUSIONS We found no significant association between coffee consumption and the risk of hip fracture. A nonlinear association emerged between tea consumption and the risk of hip fracture; individuals drinking 1-4 cups of tea per day exhibited a lower risk of hip fractures than those who drank no tea. The association between 5 daily cups of tea, or more, and hip fracture risk should be investigated.
Collapse
|
193
|
Xu K, Hao Y, Qi H. Intraocular lens power calculations using a Scheimpflug camera to measure corneal power. Biotech Histochem 2013; 89:348-54. [DOI: 10.3109/10520295.2013.867532] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
194
|
Hao Y, Lang K, Huang H, Federico V, Rogerio JW, Menzin J. Abstract P4-12-04: Initial treatment and survival among elderly breast cancer patients by receipt of human epidermal growth factor receptor 2-targeted therapy: An analysis of US national data 2006-2009. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: There are few studies of initial treatment and survival among elderly, newly diagnosed breast cancer (BC) patients stratified by receipt of human epidermal growth factor receptor 2- (HER2-) targeted therapy.
METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER) and Medicare claims and enrollment data from 2006-2009, women aged 65+ years with an incident diagnosis of BC (index date) in 2007 and no prior history of any other cancer were identified and followed to evaluate initial treatment and survival. Study patients were required to have continuous enrollment from 1 year before index (baseline period) through the end of the data window, disenrollment or death, whichever came first. Patients were classified as having received HER2-targeted therapy if they had any claim indicating trastuzumab or lapatinib following diagnosis. Demographics, initial treatment (within 4 months of diagnosis), and survival (proportion of patients who died during the study period) were evaluated by receipt of HER2-targeted therapy (and by age and stage among those who received HER2-targeted therapy). Kaplan-Meier (KM) survival curves and survival at 36 months were estimated by stage. Treatment included surgery, radiation, chemotherapy, biologic, and hormone therapy, and was evaluated among patients with > 2 months of follow-up.
RESULTS: Among 11,238 female BC patients, 510 received HER2-targeted therapy (99.8% trastuzumab, 2.5% lapatinib) and 10,728 did not. Those who received HER2-targeted therapy were slightly younger at diagnosis (mean age 73 vs. 76, P<0.01) and less likely to have positive estrogen receptor (ER+; 52.7 vs. 85.1%, P<0.01) and progesterone receptor (PR+; 37.8 vs. 72.6%, P<0.01) status. They were also more likely to be diagnosed at later stages (Stage III: 23.3 vs. 7.4%; Stage IV: 10.6 vs. 4.9%; P<0.01). Patients with HER2-targeted therapy were less likely to receive surgery (87.5 vs. 91.9%; P = 0.06), radiation (39.0 vs. 43.2%; P<0.01), or hormone therapy (6.9 vs. 16.8%, P<0.01), but more likely to receive chemotherapy (69.8 vs. 12.6%, P<0.01). Mortality was similar between the two groups (15.3% for HER2-targeted therapy vs. 16.1% for non HER2-targeted therapy, P = 0.71). Among patients receiving HER2-targeted therapy, increased age (P<0.01) and later stage (P<0.01) were associated with higher mortality. Older patients were more likely to receive hormone therapy (P = 0.02) and less likely to receive chemotherapy (P = 0.02) and surgery (P = 0.08). Patients in later stages were less likely to receive surgery (P<0.01) or radiation (P<0.01) and more likely to receive chemotherapy (P = 0.01) or hormone therapy (P = 0.05).
CONCLUSIONS: Elderly, newly diagnosed BC patients who received HER2-targeted therapy were younger than those who did not received HER2-targeted therapy. Initial treatment patterns varied between the two groups, but survival outcomes were similar. Among patients in the HER2-targeted therapy group, treatment characteristics also differed by disease stage and age.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-04.
Collapse
|
195
|
Hao Y, Landsman-Blumberg P, Meyer N, Johnson W, Willemann Rogerio J. Abstract P3-06-11: Disease and treatment characteristics of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-06-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This retrospective administrative claims study of women diagnosed with advanced or metastatic breast cancer (BC) compared clinical histories and BC treatment by receipt of HER2- targeted agents (2TA), disease stage, and age group.
Women ≥ 18 years, diagnosed with stage III or IV BC were selected from the 2008-2012 Truven Health MarketScan databases using ICD-9-CM codes on non-diagnostic medical claims corresponding to BC and local or distant metastases; date of first metastasis was the index date. Patients were followed until the earliest of end of enrollment, inpatient death or 12/31/2012. Those with <12 months continuous enrollment (CE) or non-BC primary cancers pre-index, or HIV or pregnancy anytime were excluded. 2TA was defined as ≥1 medical or pharmacy claim for trastuzumab or lapatinib in the pre- or post-index periods. Study cohorts were women ± 2TA use, 2TA users with stage III and IV BC, and 2TA users age 18-44, 45-64, or 65+ at index. Index demographics, pre-index BC and clinical histories, and post-index BC treatments were compared using t-tests, one-way ANOVA, and chi-square statistics.
Of 30,660 eligible women, 14.4% received 2TA at sometime. Compared to non-2TA patients those with 2TA were younger (mean (SD) age 55 (11) vs. 59 (13) years; p≤0.001) and had significantly lower comorbidity burden. While pre-index BC was similar (48% each), 2TA patients had higher rates of pre-index BC surgery (20% vs. 17%), adjuvant/neoadjuvent chemotherapy (74% vs. 53%), radiation treatment (12% vs. 10%), and lower non-2TA biologics use (0% vs. 3%), all p<0.005. Of the 2TA cohort with pre-index BC, 58% used 2TA pre-index. Also among 2TA patients, 57% had Stage III BC at index and 18% were 18-44, 68% 45-64 and 15% 65+. Pre-index BC diagnosis differed by index BC stage (30% III vs. 73% IV) and increased with age (44% 18-44, 48% 45-64, 54% 65+), both p<0.001.
Of those with ≥ 3 months CE post-index, 2TA users had higher rates, p<0.001 of BC surgery (53% vs. 47%), radiation (65% vs. 54%) and non-2TA antineoplastic treatment (AT: 89% vs. 83%), compared to non-2TA patients. Of those treated, 2TA users had a higher rate of chemotherapy use (85% vs. 58%), but lower use rates of hormone therapy (56% vs. 78%) and non-2TA biologics (5% vs. 8%), all p<0.001. Receipt of post-index BC surgery was greater among 2TA stage III than stage IV patients (78% vs. 19%) and decreased with age (62% 18-44, 53% 45-64, 42% 65+), both p<0.001. Post-index, stage III 2TA patients were more likely (p<0.001) to have radiation therapy (72% vs. 56%), use 2TA agents post-index (97% vs. 91%), and other AT (92% vs. 84%) compared to stage IV 2TA patients. Radiation declined in the 2TA cohort post-index with increasing age (70%, 65%, 61%, p<0.001). 2TA and AT use also declined with increasing age but these did not reach statistical significance.
Receipt of 2TA (vs. non-2TA) was significantly associated with younger age and receipt of pre- and post- BC treatments. Clinical history and BC treatment differences between these cohorts partly reflect differential treatment patterns of HER2- positive and HER2- negative BC patients. Treatment characteristics for the 2TA cohort differ by disease stage and age group.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-11.
Collapse
|
196
|
Engel-Nitz NM, Hao Y, Gomez Rey G, Sullivan J, Willemann Rogerio J. Abstract P3-06-09: Survival among patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: A real-world observational study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-06-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Little is known about real-world outcomes for patients with HR+/HER2- advanced breast cancer. This study examined mortality outcomes, and in particular variations across patients with different stages of cancer and different sequencing of endocrine and chemotherapy treatments.
Methods: This retrospective study linked medical and pharmacy claims (2008-2012) from a large national US health plan with a proprietary clinical cancer database containing physician-reported clinical data on patients with breast cancer. Patients included in the study had HR+ and HER2- status, and had stage III (S3) or IV (S4) cancer at initial diagnosis, or had developed metastases following initial diagnosis (MET). The first date of diagnosis of advanced cancer or the first date of metastases following initial diagnosis was designated as the index date. Health plan enrollment for 3 months pre- and ≥12-months post- index date was required; patients who died within 12 months after index date and were continuously enrolled in the health plan were retained. A 3-month baseline period assessed prior treatment; a variable follow-up (until disenrollment or 31 Oct 2012) assessed patterns of endocrine and chemotherapy treatments following the index date. Patient mortality was identified via a combination of Social Security mortality data and patient hospital discharge status from claims data. Chi-square tests compared proportions and t-tests compared means.
Results: The study population included 263 S3, 71 S4, and 317 MET patients. Average age at index date was 51.9 years for S3, 54.4 years for SIV, and 52.8 years for MET patients (P = 0.080). Over the entire observable follow-up, 3.4% of S3 (17 per 1000 patient-years), 22.5% of S4 (119 per 1000 patient years), and 10.7% of MET patients (22 per 1000 patient years) died (P≤0.010 for comparisons). Mortality over the 1-year after index date was 1.1%, 12.7%, and 5.1% in the S3, S4, and MET groups respectively (P<0.001). Patients who died in the first year after index date survived on average until 5.8 months (S3), 4.5 months (S4), and 7.3 months (MET) following the metastatic index date. Among MET patients, mean time to death from initial breast cancer diagnosis was 35.7 months for MET patients without endocrine treatment prior to chemotherapy (n = 157), and 76.1 months for other MET patients (n = 160) (P = 0.002). For S4 patients without endocrine treatment prior to chemotherapy (n = 34), patients survived an average of 10.0 months from initial advanced breast cancer diagnosis while the remaining S4 patients (n = 37) survived an average of 14.8 months.
Conclusions: Among patients with HR+/HER2- advanced breast cancer, mortality rates varied by stage of disease, and length of survival varied across patients pre-treated with endocrine therapy prior to chemotherapy compared with other patients. Further investigation of drivers behind differences in mortality may reveal the extent to which initial disease severity and sequencing of chemotherapy and endocrine therapy drive these variations.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-09.
Collapse
|
197
|
Hao Y, Lang K, Huang H, Federico V, Menzin J. Abstract P3-06-10: All-cause resource use among elderly breast cancer patients by receipt of human epidermal growth factor receptor 2-targeted therapy: An analysis of US national data 2006-2009. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-06-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: There are few recent studies of all-cause resource use among elderly, newly diagnosed breast cancer (BC) patients by receipt of human epidermal growth factor receptor 2- (HER2-) targeted therapy.
METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER) and Medicare claims and enrollment data from 2006-2009, women aged 65+ years with an incident diagnosis of BC (index date) in 2007 and no prior history of any other cancer were identified and followed to evaluate all-cause resource use. Study patients were required to have continuous enrollment from 1 year before index (baseline period) through the end of the data window, disenrollment or death, whichever came first. Patients were classified as having received HER2-targeted therapy if they had any claim indicating trastuzumab or lapatinib following diagnosis. Demographics and all-cause resource use (hospitalizations, hospital days, outpatient visits, physician/provider services, prescription drug use, skilled nursing facility [SNF] care, home health care, hospice care, and durable medical equipment) were evaluated by receipt of HER2-targeted therapy (and by stage and age among those treated with HER2-targeted therapy).
RESULTS: Among 11,238 female BC patients, 510 received HER2-targeted therapy (99.8% trastuzumab, 2.5% lapatinib) and 10,728 did not. Duration of follow-up was longer for the HER2- targeted therapy group (mean: 28.0 vs. 27.2 months, P = 0.06). Patients receiving HER2-targeted therapy were more likely to be hospitalized during follow-up (72.4% vs. 57.8%, P<0.01), though they had fewer mean per-patient-per-month (PPPM) hospital days (0.38 vs. 0.49, P<0.01). Almost all patients had an outpatient visit (100.0% and 97.3%, P<0.01) and a physician/provider visit (100.0% and 99.6%, P = 0.42) during follow-up, though patients receiving HER2-targeted therapy experienced greater PPPM service use (mean outpatient visits 1.08 vs. 0.69, P<0.01; mean physician/provider services 3.91 vs. 2.79, P<0.01). Similar proportions of patients had prescription drug (61.2% vs. 57.7%, P = 0.12), SNF care (14.3% vs. 14.5%, P = 0.95), and hospice care (both 8.2%, P = 1.00) use. Among patients treated with HER2-targeted therapy, those with later stage cancer were more likely to receive SNF (8.6% [Stage I], 11.8% [Stage II], 16.8% [Stage III], 27.8% [Stage IV]; P<0.01), home health (20.7%, 39.6%, 50.4%, 50.0%; P<0.01), and hospice care (0.0%, 0.5%, 15.1%, 31.5%; P<0.01), and had higher mean PPPM hospital days (0.23, 0.32, 0.47, 0.73; P<0.01). Patients treated with HER2-targeted therapy aged 75+ were more likely to be hospitalized (64.7% [65-69], 73.3% [70-74], 79.4% [75+]; P = 0.01) and to receive SNF (12.4%, 10.0%, 21.3%; P = 0.01), home health (31.2%, 35.6%, 51.9%; P<0.01), and hospice care (5.3%, 4.4%, 15.6%; P<0.01).
CONCLUSIONS: Patients receiving HER2-targeted therapy were more likely to be hospitalized than those not receiving HER2-targeted therapy, although with fewer mean PPPM hospital days. Outpatient and physician visits also were more frequent in the HER2-targeted therapy group. Among those receiving HER2-targeted therapy, resource use was higher among those diagnosed at later stages and advanced ages.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-10.
Collapse
|
198
|
Ali A, Bane F, Hao Y, McCartan D, O'Gaora P, Hill ADK, Young LS, McIlroy M. Abstract PD3-5: Survival benefit conferred by the androgen receptor is lost in aromatase inhibitor treated breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd3-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aromatase Inhibitors have proven to be most effective in the treatment of post-menopausal breast cancer. Their mode of action is to inhibit the synthesis of estrogen (estrone) by the aromatase enzyme Cyp 19 thereby blocking ligand-dependent activation of the estrogen receptor. What has not been addressed to date is how cells that are deprived of estrogen, may potentially, adapt to the more androgenic environment resulting from long-term treatment with AI therapy. Research from our lab has identified the homeobox protein, HOXC11, to be an indicator of poor response to endocrine therapy and development of metastasis. To further our understanding of HOXC11 and its role in the development of endocrine-resistance and metastatic spread we undertook an RNA-seq experiment to identify its target genes in resistant breast cancer. This analysis identified PSAP, IFIT1 and HSP90AA1. Both PSAP (an androgen agonist) and HSP90AA1 (AR chaperone) are closely associated with AR which led to further investigation into the role of HOXC11 in the development of steroidal adaptability in Letrozole-resistant breast cancer. We hypothesize that HOXC11 regulated expression of PSAP results in oncogenic activation of AR in an AI resistant setting. Our findings have shown that AI-resistant cell lines in vitro have significantly elevated levels of AR and that loss of HOXC11 results in concommitant decrease in AR mRNA. In AI resistance expression of HOXC11 results in upregulation/stabilization of AR by PSAP thus enabling the tumour to adapt to use androgenic steroids for cell proliferation. The anti-androgen, Bicalutamide, reduces cell proliferation and cell motility in AI resistant cell lines. Survival analysis of AR in a TMA (n = 488) indicates that AR confers a survival benefit in the tamoxifen treated population. This protective effect is diminished in patients receiving AI therapy and is reflected in the altered Hazard Ratio of AR from the total population (HR: 0.485) to the AI treated cohort (HR: 1.197). Secreted PSAP was readily detectable in breast cancer patient serum and associates significantly with expression of HOXC11 in matched patient tissue (∼20). PSAP is associated with poor response to endocrine therapy and metastatic spread of prostate cancer and as it is secreted it could potentially be used to monitor patients on AI who might benefit from dual targeted therapy treatment.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD3-5.
Collapse
|
199
|
Engel-Nitz NM, Hao Y, Gomez Rey G, Sullivan J, Willemann Rogerio J. Abstract P3-06-08: Patterns of health care utilization and costs by chemotherapy and endocrine therapy sequencing among patients with hormone receptor positive (HR+)/HER2- negative advanced breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-06-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Little is known about health care costs and health services utilization of patients with HR+/HER2- advanced breast cancer, particularly in relation to the order in which patient receive endocrine and chemotherapy treatments.
Methods: A proprietary database with physician-reported clinical data on patients with breast cancer was linked to medical and pharmacy claims (2008-2012) from a national US health plan. Patients included in the study had HR+ and HER2- status. Advanced cancer included stage III or IV (SIV) at initial diagnosis, or developed metastases following initial diagnosis. The first date of advanced cancer diagnosis or date of metastases following initial diagnosis was designated as the index date. Health plan enrollment for 3 months pre- and ≥12-months post- index date was required; patients who died within 12 months after index date and were continuously enrolled were retained. A 3-month baseline period assessed prior treatment; variable follow-up (until disenrollment or 31 Oct 2012) assessed patterns of endocrine and chemotherapy treatments following index date. All-cause and cancer-specific health care utilization and paid costs were assessed over 12-months following index date. Costs were calculated as per-patient-per-month (PPPM), and utilization measured as rates per patient-month. Cancer-related medication costs included drug costs for endocrine, chemotherapy, targeted therapy, and treatments for pain or chemotherapy-induced nausea/ vomiting. In addition, costs for anti-cancer systemic therapies (chemotherapy, endocrine, and targeted therapy) were calculated PPPM including costs for medication administration.
Results: Of 651 study patients, 65% initiated chemotherapy prior to initiating endocrine therapy (CH). Remaining patients (OT) either had no chemotherapy (n = 132 endocrine only, n = 16 neither endocrine nor chemotherapy), or used endocrine therapy prior to chemotherapy (n = 77). Compared with OT, the CH group had more office (4.04 vs. 2.68 visits, P<0.001) and outpatient hospital visits (3.08 vs. 2.10 visits, P<0.001). In addition, 56% of CH vs. 41% of OT had inpatient hospital admissions during the follow-up (P<0.001; rate ratio 0.97, P = NS). Similarly, 60% of CH patients were admitted to emergency rooms vs. 51% of OT (P = 0.033; rate ratio 1.01, P = NS). Mean total all-cause health care costs varied ($11,525 CH vs. $8,196 OT, P<0.001). The largest source of difference in costs were office visits (mean $3,257 CH vs. $1,896 OT, P<0.001), and outpatient hospital ($5,813 CH vs. $3,721 OT, P<0.001). Cancer-related costs comprised the majority of costs (mean $10,249 CH vs. $7,118 OT, P<0.001). The CH group had higher mean cancer-related medication costs than the OT group ($2,051 vs. $1,405 respectively, P = 0.040). Overall mean anti-cancer systemic therapy costs (including administration) were higher in the CH than OT group ($2,934 vs. $1,875, P = 0.012).
Conclusions: Among HR+/HER2- advanced breast cancer patients, health care utilization and costs were higher for patients who initiated chemotherapy prior to endocrine therapy compared to other patients. Further investigation of the drivers behind these differences is warranted.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-08.
Collapse
|
200
|
Hao Y, Engel-Nitz NM, Sullivan J, Henk HJ, Willemann Rogerio J, Newcomer L. Abstract P1-14-03: Chemotherapy and endocrine therapy treatment patterns among patients with hormone receptor positive (HR+)/HER2 negative advanced breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-14-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: National Comprehensive Cancer Network breast cancer guidelines suggest optimized sequencing of endocrine therapy prior to chemotherapy use for patients who are HR+/HER2-, but it is unclear how those recommendations translate into clinical practice. This study examined sequencing of endocrine and chemotherapy treatment to better understand real-world treatment patterns for HR+/HER2- advanced breast cancer.
Methods: This retrospective study examined physician-reported clinical data on patients with breast cancer (BC) linked to medical and pharmacy claims (2008-2012) from a large national US health plan. Patients included in the study had HR+ and HER2- status. Advanced cancer cohorts included patients who were stage IV (SIV) at initial diagnosis, or who developed metastases following initial diagnosis (MET). The first date of diagnosis of advanced cancer or date of metastases following initial diagnosis was designated as index date. Health plan enrollment for 3 months pre- and ≥12-months post- index date was required; patients who died within 12 months after index date and were continuously enrolled were retained. A 3-month baseline period assessed prior treatment; variable post-index follow-up (until disenrollment or Oct 2012) assessed patterns of endocrine and chemotherapy.
Results: Of 317 MET patients, 50% initiated chemotherapy after index date without prior endocrine treatment (CH). Remaining patients (OT) used only endocrine therapy (30%), endocrine therapy prior to chemotherapy (17%), or neither endocrine nor chemotherapy (3%). Compared with OT patients, CH patients were younger (50 vs. 55 years, P<0.001) and progressed faster to metastasis after initial BC diagnosis (243 vs. 1633 days, P<0.001). Although CH patients in the MET group had slightly higher comorbidity prior to their metastatic index date, they had lower levels of any non-lymph node metastases (14% vs. 48%, P<0.001) and visceral metastases (5% vs. 16%, P = 0.001) during follow-up. Among MET patients, 92% of CH patients initiated endocrine therapy during follow-up; endocrine therapy started a mean of 235 days after metastatic index date, compared with a mean starting date for chemotherapy of 41 days post-metastatic index date. In the MET group, 55% of CH later initiated treatment with aromatase inhibitors, compared with 64% of OT patients (P = 0.104). Results were similar in newly diagnosed SIV (n = 71) group: 48% had no evidence of endocrine treatment prior to initiating chemotherapy, and remaining patients used only endocrine therapy (27%), had endocrine therapy prior to chemotherapy (21%), or neither therapy (4%).
Conclusions: In this population of patients with HR+/HER2- advanced breast cancer, a large proportion initiated chemotherapy without prior endocrine therapy. This group of patients might otherwise benefit from a longer progression free period with tolerable toxicity from endocrine therapy. Further investigation of whether a subgroup of these patients started chemotherapy in the adjuvant setting is warranted. For those starting chemotherapy without prior endocrine therapy, understanding treatment sequencing and patient characteristics will help illuminate the extent to which patterns adhere to NCCN guidelines.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-14-03.
Collapse
|